BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sees Unusually-High Trading Volume – Time to Buy?

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) shares saw unusually-high trading volume on Monday . Approximately 243,081 shares changed hands during mid-day trading, a decline of 14% from the previous session’s volume of 282,410 shares.The stock last traded at $8.9550 and had previously closed at $8.40.

Wall Street Analysts Forecast Growth

BBOT has been the topic of several research reports. Weiss Ratings initiated coverage on shares of BridgeBio Oncology Therapeutics in a research note on Wednesday, January 14th. They issued a “sell (d+)” rating on the stock. Stifel Nicolaus initiated coverage on shares of BridgeBio Oncology Therapeutics in a research note on Tuesday, February 10th. They issued a “buy” rating and a $23.00 price objective on the stock. HC Wainwright increased their price target on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Finally, Raymond James Financial upgraded shares of BridgeBio Oncology Therapeutics to a “moderate buy” rating in a research note on Friday, January 9th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $26.00.

BridgeBio Oncology Therapeutics Stock Performance

The firm has a 50 day simple moving average of $9.75. The firm has a market cap of $734.68 million, a P/E ratio of -6.04 and a beta of 0.51.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of BBOT. XTX Topco Ltd grew its stake in BridgeBio Oncology Therapeutics by 22.4% in the 4th quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock valued at $358,000 after buying an additional 5,249 shares during the last quarter. State Street Corp grew its stake in BridgeBio Oncology Therapeutics by 23.5% in the 4th quarter. State Street Corp now owns 218,278 shares of the company’s stock valued at $2,733,000 after buying an additional 41,583 shares during the last quarter. Geode Capital Management LLC grew its stake in BridgeBio Oncology Therapeutics by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock valued at $7,039,000 after buying an additional 20,385 shares during the last quarter. Paradigm Biocapital Advisors LP grew its stake in BridgeBio Oncology Therapeutics by 21.2% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company’s stock valued at $28,317,000 after buying an additional 395,608 shares during the last quarter. Finally, Laurion Capital Management LP grew its stake in BridgeBio Oncology Therapeutics by 40.1% in the 4th quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company’s stock valued at $18,341,000 after buying an additional 419,138 shares during the last quarter. Institutional investors and hedge funds own 54.89% of the company’s stock.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.